S&P 500   4,236.01 (+0.61%)
DOW   33,534.02 (+0.67%)
QQQ   326.19 (+0.08%)
AAPL   169.39 (+0.09%)
MSFT   288.42 (-0.26%)
META   178.33 (+-0.01%)
GOOGL   119.51 (-0.16%)
AMZN   141.83 (-0.60%)
TSLA   870.52 (-1.42%)
NVDA   181.44 (+0.26%)
NIO   21.08 (+5.14%)
BABA   95.19 (+2.99%)
AMD   99.67 (+0.63%)
MU   62.78 (+2.25%)
T   18.13 (+0.67%)
CGC   3.21 (-2.43%)
GE   79.05 (+2.48%)
F   15.84 (+2.19%)
DIS   118.97 (+5.82%)
AMC   24.92 (+5.28%)
PYPL   100.22 (+1.32%)
PFE   47.97 (-3.96%)
NFLX   246.23 (+0.87%)
S&P 500   4,236.01 (+0.61%)
DOW   33,534.02 (+0.67%)
QQQ   326.19 (+0.08%)
AAPL   169.39 (+0.09%)
MSFT   288.42 (-0.26%)
META   178.33 (+-0.01%)
GOOGL   119.51 (-0.16%)
AMZN   141.83 (-0.60%)
TSLA   870.52 (-1.42%)
NVDA   181.44 (+0.26%)
NIO   21.08 (+5.14%)
BABA   95.19 (+2.99%)
AMD   99.67 (+0.63%)
MU   62.78 (+2.25%)
T   18.13 (+0.67%)
CGC   3.21 (-2.43%)
GE   79.05 (+2.48%)
F   15.84 (+2.19%)
DIS   118.97 (+5.82%)
AMC   24.92 (+5.28%)
PYPL   100.22 (+1.32%)
PFE   47.97 (-3.96%)
NFLX   246.23 (+0.87%)
S&P 500   4,236.01 (+0.61%)
DOW   33,534.02 (+0.67%)
QQQ   326.19 (+0.08%)
AAPL   169.39 (+0.09%)
MSFT   288.42 (-0.26%)
META   178.33 (+-0.01%)
GOOGL   119.51 (-0.16%)
AMZN   141.83 (-0.60%)
TSLA   870.52 (-1.42%)
NVDA   181.44 (+0.26%)
NIO   21.08 (+5.14%)
BABA   95.19 (+2.99%)
AMD   99.67 (+0.63%)
MU   62.78 (+2.25%)
T   18.13 (+0.67%)
CGC   3.21 (-2.43%)
GE   79.05 (+2.48%)
F   15.84 (+2.19%)
DIS   118.97 (+5.82%)
AMC   24.92 (+5.28%)
PYPL   100.22 (+1.32%)
PFE   47.97 (-3.96%)
NFLX   246.23 (+0.87%)
S&P 500   4,236.01 (+0.61%)
DOW   33,534.02 (+0.67%)
QQQ   326.19 (+0.08%)
AAPL   169.39 (+0.09%)
MSFT   288.42 (-0.26%)
META   178.33 (+-0.01%)
GOOGL   119.51 (-0.16%)
AMZN   141.83 (-0.60%)
TSLA   870.52 (-1.42%)
NVDA   181.44 (+0.26%)
NIO   21.08 (+5.14%)
BABA   95.19 (+2.99%)
AMD   99.67 (+0.63%)
MU   62.78 (+2.25%)
T   18.13 (+0.67%)
CGC   3.21 (-2.43%)
GE   79.05 (+2.48%)
F   15.84 (+2.19%)
DIS   118.97 (+5.82%)
AMC   24.92 (+5.28%)
PYPL   100.22 (+1.32%)
PFE   47.97 (-3.96%)
NFLX   246.23 (+0.87%)
NASDAQ:MEDP

Medpace - MEDP Stock Forecast, Price & News

$181.50
+4.83 (+2.73%)
(As of 08/11/2022 01:02 PM ET)
Add
Compare
Today's Range
$177.25
$183.53
50-Day Range
$132.27
$176.67
52-Week Range
$126.94
$231.00
Volume
7,449 shs
Average Volume
358,131 shs
Market Capitalization
$5.63 billion
P/E Ratio
31.51
Dividend Yield
N/A
Price Target
$175.00

Medpace MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
3.5% Downside
$175.00 Price Target
Short Interest
Healthy
7.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.46mentions of Medpace in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$4.43 M Bought Last Quarter
Proj. Earnings Growth
5.68%
From $6.16 to $6.51 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

514th out of 1,112 stocks

Commercial Physical Research Industry

8th out of 17 stocks

MEDP stock logo

About Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on MEDP shares. Guggenheim started coverage on shares of Medpace in a research report on Monday, May 23rd. They issued a "neutral" rating on the stock. StockNews.com upgraded shares of Medpace from a "hold" rating to a "buy" rating in a research report on Thursday, July 28th.

Medpace Stock Up 4.4 %

Shares of NASDAQ:MEDP traded up $7.51 during trading on Wednesday, hitting $176.67. The company had a trading volume of 261,423 shares, compared to its average volume of 342,929. The stock has a fifty day simple moving average of $152.21 and a two-hundred day simple moving average of $152.47. Medpace has a fifty-two week low of $126.94 and a fifty-two week high of $231.00. The firm has a market capitalization of $5.48 billion, a price-to-earnings ratio of 30.36 and a beta of 1.43.

Medpace (NASDAQ:MEDP - Get Rating) last posted its quarterly earnings results on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.13. The firm had revenue of $351.21 million for the quarter, compared to the consensus estimate of $344.01 million. Medpace had a net margin of 16.27% and a return on equity of 30.56%. The company's revenue for the quarter was up 26.2% on a year-over-year basis. During the same period last year, the firm posted $1.06 earnings per share. On average, analysts anticipate that Medpace will post 6.16 earnings per share for the current year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle purchased 8,330 shares of the firm's stock in a transaction dated Monday, July 18th. The shares were purchased at an average cost of $145.00 per share, with a total value of $1,207,850.00. Following the completion of the purchase, the chief executive officer now owns 5,513,639 shares in the company, valued at approximately $799,477,655. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO August J. Troendle bought 22,290 shares of Medpace stock in a transaction on Thursday, July 14th. The shares were bought at an average cost of $144.59 per share, with a total value of $3,222,911.10. Following the completion of the purchase, the chief executive officer now directly owns 5,505,309 shares of the company's stock, valued at $796,012,628.31. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle bought 8,330 shares of Medpace stock in a transaction on Monday, July 18th. The shares were purchased at an average cost of $145.00 per share, for a total transaction of $1,207,850.00. Following the completion of the purchase, the chief executive officer now directly owns 5,513,639 shares of the company's stock, valued at $799,477,655. The disclosure for this purchase can be found here. Insiders own 20.60% of the company's stock.

Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Stock News Headlines

3 Reasons Growth Investors Will Love Medpace (MEDP)
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Company Calendar

Last Earnings
7/25/2022
Today
8/11/2022
Next Earnings (Estimated)
10/24/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
4,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$175.00
High Stock Price Forecast
$175.00
Low Stock Price Forecast
$175.00
Forecasted Upside/Downside
-3.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$181.85 million
Pretax Margin
18.50%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$6.04 per share
Book Value
$9.14 per share

Miscellaneous

Free Float
24,613,000
Market Cap
$5.63 billion
Optionable
Optionable
Beta
1.43














MEDP Stock - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price forecast for 2022?

1 equities research analysts have issued 12 month price objectives for Medpace's shares. Their MEDP share price forecasts range from $175.00 to $175.00. On average, they predict the company's stock price to reach $175.00 in the next year. This suggests that the stock has a possible downside of 0.9%.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2022?

Medpace's stock was trading at $217.64 on January 1st, 2022. Since then, MEDP stock has decreased by 18.8% and is now trading at $176.67.
View the best growth stocks for 2022 here
.

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 24th 2022.
View our MEDP earnings forecast
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings data on Monday, July, 25th. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.13. The business had revenue of $351.21 million for the quarter, compared to the consensus estimate of $344.01 million. Medpace had a net margin of 16.27% and a trailing twelve-month return on equity of 30.56%. Medpace's quarterly revenue was up 26.2% on a year-over-year basis. During the same quarter last year, the business posted $1.06 EPS.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY 2022 earnings guidance on Monday, August, 1st. The company provided earnings per share guidance of $6.07-$6.36 for the period, compared to the consensus estimate of $5.82. The company issued revenue guidance of $1.41 billion-$1.44 billion, compared to the consensus revenue estimate of $1.40 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by many different institutional and retail investors. Top institutional shareholders include Boston Trust Walden Corp (2.05%), Riverbridge Partners LLC (1.43%), TD Asset Management Inc. (0.86%), Loomis Sayles & Co. L P (0.78%), Eagle Asset Management Inc. (0.67%) and Rice Hall James & Associates LLC (0.60%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $176.67.

How much money does Medpace make?

Medpace (NASDAQ:MEDP) has a market capitalization of $5.48 billion and generates $1.14 billion in revenue each year. The company earns $181.85 million in net income (profit) each year or $5.76 on an earnings per share basis.

How many employees does Medpace have?

The company employs 4,500 workers across the globe.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.

This page (NASDAQ:MEDP) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.